SCHEMBL2497304

SCHEMBL2497304

C1=Nc2c(-c3cccs3)ccnc2[N]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.37
GFER P55789 1/20 0.37
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CYP19A1 P11511 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
TOP2A P11388 1/20 0.36
CDK5 Q00535 2/20 0.36
LTK P29376 1/20 0.36
MST1R Q04912 1/20 0.36
DYRK1A Q13627 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11904077 0.90 DPP4 (0.38) KDM4EALDH1A1GAAGFERCYP19A1
SCHEMBL2498595 0.75 CYP17A1 (0.38) TGFBR1CYP2A6CYP17A1RAB9A
SCHEMBL1033845 0.75 NPC1 (0.43) KDM4EALDH1A1GAAGFERCYP3A4
SCHEMBL1023476 0.74 RPS6KB2 (0.37) KDM4EALDH1A1GAACYP19A1CDK5
SCHEMBL28083058 0.71 TOP2A (0.49) KDM4EALDH1A1GAAGFERCCNA2
SCHEMBL2493981 0.71 KDM4E (0.41) KDM4EALDH1A1GAAGFERCCNA2
SCHEMBL3358739 0.67 TOP2A (0.59) KDM4EALDH1A1GAAGFERCCNA2
SCHEMBL1023046 0.67 ADORA2A (0.51) KDM4EALDH1A1GAACDK5CDK5R1
SCHEMBL28755209 0.66 CDK5 (0.45) KDM4EALDH1A1GAAGFERCCNA2
SCHEMBL2495572 0.66 KDM4E (0.50) KDM4EALDH1A1GAAGFERCCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024111671-A1 NUCLEIC ACID APTAMER ゼノリス プライベート リミテッド 2024-05-30 WO claimed
EP-3369820-B1 DNA APTAMER CAPABLE OF BONDING TO VWF TAGCYX BIOTECHNOLOGIES INC (JP) 2021-12-08 EP claimed
EP-3918091-A1 METHOD OF SEQUENCING NUCLEIC ACID WITH UNNATURAL BASE PAIRS Agency for Science, Technology and Research (SG) 2021-12-08 EP claimed
EP-3266871-B1 METHOD FOR STABILIZING DNA APTAMERS TAGCYX BIOTECHNOLOGIES INC (JP) 2021-04-28 EP claimed
EP-3369819-B1 DNA APTAMER BINDING TO CANCER CELL AGENCY SCIENCE TECH & RES (SG) 2020-11-18 EP claimed
US-10837964-B2 DNA aptamer binding to cancer cell AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-11-17 US claimed
US-10760083-B2 DNA aptamer that binds to vWF TAGCYX BIOTECHNOLOGIES INC. (JP) 2020-09-01 US claimed
WO-2020159435-A1 METHOD OF SEQUENCING NUCLEIC ACID WITH UNNATURAL BASE PAIRS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-08-06 WO claimed
US-10550393-B2 Method for stabilizing DNA aptamers TAGCYX BIOTECHNOLOGIES (JP) 2020-02-04 US claimed
US-20190345499-A1 METHOD FOR STABILIZING DNA APTAMERS TAGCYX BIOTECHNOLOGIES (JP) 2019-11-14 US claimed
US-20130122506-A1 NUCLEIC ACID BASE ANALOGS WITH QUENCHING AND FLUORESCENT ACTIVITIES AND APPLICATIONS THEREOF TAGCYX BIOTECHNOLOGIES C/O RIKEN (JP) 2013-05-16 US claimed
EP-2562255-A1 NUCLEIC ACID BASE ANALOG WITH QUENCHING CHARACTERISTICS AND FLUORESCENCE AND APPLICATION THEREOF Riken (JP) 2013-02-27 EP claimed
EP-1970445-B1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS RIKEN (JP) 2012-09-26 EP claimed
US-20120231462-A1 ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR TAGCYX BIOTECHNOLOGIES (JP) 2012-09-13 US claimed
EP-2487181-A1 ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR Riken (JP) 2012-08-15 EP claimed
US-8030478-B2 Method for nucleic acid replication and novel artificial base pairs RIKEN (JP) 2011-10-04 US claimed
US-20100323364-A1 MODIFIED tRNA CONTAINING UNNATURAL BASE AND USE THEREOF THE UNIVERSITY OF TOKYO (JP) 2010-12-23 US claimed
EP-2246428-A1 MODIFIED TRNA CONTAINING NON-NATURAL NUCLEOTIDE AND USE THEREOF The University of Tokyo (JP) 2010-11-03 EP claimed
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS RIKEN (JP) 2010-02-11 US claimed
EP-1970445-A1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS Riken (JP) 2008-09-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS POLM, POLL, POLRMT KDM4E 1933/4885ALDH1A1 2586/4885GAA 1766/4885
US-20120231462-A1 ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR NSUN2, EIF2AK2, NSUN3 KDM4E 3694/4885ALDH1A1 1963/4885GAA 1909/4885
US-20100323364-A1 MODIFIED tRNA CONTAINING UNNATURAL BASE AND USE THEREOF TRMT1, NSUN3, TARBP1 KDM4E 2184/4885ALDH1A1 3848/4885GAA 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.